Navigation Links
Cancer publishes study confirming disparity in breast cancer treatment
Date:2/16/2010

WILMINGTON, Del.Feb. 16, 2010Cancer, the peer-reviewed international journal of the American Cancer Society, has published a study conducted by HealthCore, Inc. in its Jan. 1 edition, demonstrating disparities in breast cancer treatment between commercially insured African-American and white women.

The HealthCore study reiterates the findings of previous studies conducted in populations using government health programs that African-American women are diagnosed in later stages of the disease.

Breast cancer is the second most common cause of cancer death in white and African-American women in the United States.

"This study demonstrates that disparities in breast cancer care exist even when patients have access to employer-provided healthcare," said Dr. Joe Singer, HealthCore vice president for clinical affairs. "A key takeaway from our study is that African-American women were diagnosed with breast cancer at younger ages, but in later stages of breast cancer, when chances of survival diminish greatly."

The study, funded by Amgen, was conducted in collaboration with Blue Cross and Blue Shield of Georgia and the American Cancer Society. HealthCore is working with Blue Cross and Blue Shield of Georgia and the American Cancer Society to further evaluate the study to understand more about the women who are newly diagnosed with breast cancer so the health plan can determine better ways to communicate with them and their physicians in an attempt to diminish the disparities.

The HealthCore study also found that not all women who tested positive for hormone receptor cancer received anti-estrogen therapy, which is a standard of care set by guidelines established by the National Comprehensive Cancer Network and the American Cancer Society. Of those women who did test positive, white women were more likely than African-American women to receive anti-estrogen therapy.

Specifically, the study found:

  • White women (55.2 percent) were more likely than African- American women (38.4 percent) to be diagnosed with stage 0 or stage I disease.
  • Twice as many African-American women (6.1 percent) compared with white women (3.6 percent) were diagnosed with stage IV disease.
  • Among women who tested positive for hormone receptor cancer, African-American women were less likely to receive treatment, such as aromatase inhibitors or tamoxifen.
  • White women were twice as likely to receive anti-estrogen therapy compared with African-American women, after adjusting for age, cancer stage, and social economic status.

"While treatment for depression and anxiety occurred in both groups, less than half of those women had notes in their medical charts to follow-up with their primary care physician and only one women was referred to a mental health professional," said Dr. Otis Brawley, chief medical officer for the American Cancer Society and study co-author. "Clearly, this is a health intervention needed for both African-American and white women."


'/>"/>

Contact: Lori McLaughlin
lori.mclaughlin2@wellpoint.com
317-407-7403
HealthCore
Source:Eurekalert

Related medicine news :

1. The Icebox of Atlanta Selected as T-shirt Vendor for 3 Major Divisions of American Cancer Society's Relay For Life
2. New therapeutic target for most common solid cancer in childhood?
3. Certain pain medications do not appear to be associated with skin cancer risk
4. NSAIDs Wont Shield Against Skin Cancer
5. PA Breast Cancer Coalition Launches Income Tax Refund Campaign
6. Businesses Rally Big Efforts to Benefit the Susan G. Komen Phoenix Affiliates Fight Against Breast Cancer
7. Advance Toward Test for Aggressive Prostate Cancer
8. Breast Cancer Stats Differ Racially Despite Similar Mammogram Rates
9. GUMCs Lombardi Hosts Symposium Exploring Future of Cancer Research and Personalized Medicine
10. MRI May Not Add Value to Routine Breast Cancer Care
11. MSU researcher linking breast cancer patients with alternative therapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... 26, 2016 , ... Pixel Film Studios Released ProSlice Levels, a Media Slicing ... their videos a whole new perspective by using the title layers in ProSlice ... , ProSlice Levels contains over 30 Different presets to choose from. FCPX ...
(Date:6/26/2016)... Lake Orion, Clarkston, Michigan (PRWEB) , ... June ... ... direction with respect to fertility once they have been diagnosed with endometriosis. These ... tolerable intercourse but they also require a comprehensive approach that can help for ...
(Date:6/25/2016)... ... ... The temporary closing of Bruton Memorial Library on June 21 due to a possible lice ... overlooked aspect of head lice: the parasite’s ability to live away from a human host, ... a necessary one in the event that lice have simply gotten out of control. , ...
(Date:6/25/2016)... CA (PRWEB) , ... June 25, 2016 , ... As ... with Magna Cum Laude and his M.D from the David Geffen School of Medicine ... and returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive ...
(Date:6/25/2016)... Canada (PRWEB) , ... June 25, 2016 , ... Conventional ... pursuit of success. In terms of the latter, setting the bar too high can ... risk more than just slow progress toward their goal. , Research from ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... -- Research and Markets has announced the addition ... report to their offering. ... The World Market for Companion Diagnostics covers the world ... in the report includes the following: , ... by Region (N. America, EU, ROW), 2015-2020 , World ...
(Date:6/24/2016)... 2016   Pulmatrix, Inc ., (NASDAQ: ... drugs, announced today that it was added to the ... its comprehensive set of U.S. and global equity indexes ... important milestone for Pulmatrix," said Chief Executive Officer ... our progress in developing drugs for crucial unmet medical ...
(Date:6/24/2016)... KNOXVILLE, Tenn. , June 24, 2016 /PRNewswire/ ... market providing less invasive and more durable cerebrospinal ... million in funding.  The Series-A funding is led ... the Lighthouse Fund, and other private investors.  Arkis, ... less-invasive neurosurgical instrumentation and the market release of ...
Breaking Medicine Technology: